<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475057</url>
  </required_header>
  <id_info>
    <org_study_id>0102-15-RMC</org_study_id>
    <nct_id>NCT02475057</nct_id>
  </id_info>
  <brief_title>Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists</brief_title>
  <official_title>A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether Degarelix is associated with less endothelial
      dysfunction (an intermediate in the development of cardiac disease) and cardiovascular
      biomarkers compared to LHRH agonists.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a national multicenter randomized open-label superiority study of the use of
      Degarelix compared to LHRH agonists among men with advanced prostate cancer and pre-existing
      cardiovascular disease. Patients will be stratified based on baseline endothelial function
      and presence prostate cancer metastasis.

      Study population: Subjects with pre-existing cardiovascular disease with locally advanced or
      metastatic prostate cancer and scheduled to start Androgen Deprivation Therapy (ADT).
      Patients already on ADT will be excluded. subjects will receive either two initial loading
      doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months or
      an LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year. Follow-up
      visits will occur every 3 months. A blood sample for Prostate-specific antigen (PSA), cardiac
      biomarkers and rectal examination will be performed each visit. At baseline 6 and 12 months
      EndoPAT2000 measurements will be taken.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Reactive Hyperemia Index from baseline to twelve months</measure>
    <time_frame>Baseline, and twelve months</time_frame>
    <description>the Reactive Hyperemia Index is a measure of endothelial function. It will be measured using the EndoPAT2000</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in High sensitivity troponin (hsTn) value</measure>
    <time_frame>Baseline, and after three, six and twelve months of treatment initiation</time_frame>
    <description>High sensitivity troponin (hsTn) is a biomarker for acute myocardial injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive protein value</measure>
    <time_frame>Baseline, and after three, six and twelve months of treatment initiation</time_frame>
    <description>C-reactive protein is a biomarker for inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D-dimer value</measure>
    <time_frame>Baseline, and after three, six and twelve months of treatment initiation</time_frame>
    <description>D-dimer is a biomarker for coagulation system activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-terminal pro-brain natriuretic peptide (NT-proBNP) value</measure>
    <time_frame>Baseline, and after three, six and twelve months of treatment initiation</time_frame>
    <description>N-terminal pro-brain natriuretic peptide (NT-proBNP) is a biomarker for myocardial strain</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in testosterone level</measure>
    <time_frame>Baseline, and after three, six and twelve months of treatment initiation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in gonadotropins levels</measure>
    <time_frame>Baseline, and after three, six and twelve months of treatment initiation</time_frame>
    <description>LH</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in PSA value</measure>
    <time_frame>Baseline, and after three, six and twelve months of treatment initiation</time_frame>
    <description>Prostate-specific antigen</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in BMI</measure>
    <time_frame>Baseline, and after three, six and twelve months of treatment initiation</time_frame>
    <description>Body Mass Index</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Quality Of Life score</measure>
    <time_frame>Baseline, and after three, six and twelve months of treatment initiation</time_frame>
    <description>As assessed by the FACT-P quality of life questionnaire</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Degarelix (LHRH antagonist)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Degarelix (LHRH antagonist) EndoPAT2000</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LHRH agonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LHRH agonist at the discretion of the treating Urologist/Oncologist EndoPAT2000</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix (LHRH antagonist)</intervention_name>
    <description>Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.</description>
    <arm_group_label>Degarelix (LHRH antagonist)</arm_group_label>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LHRH agonist</intervention_name>
    <description>LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.</description>
    <arm_group_label>LHRH agonist</arm_group_label>
    <other_name>Luteinizing hormone-releasing hormone agonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoPAT2000</intervention_name>
    <description>Peripheral arterial plethysmography using an EndoPAT2000 device</description>
    <arm_group_label>Degarelix (LHRH antagonist)</arm_group_label>
    <arm_group_label>LHRH agonist</arm_group_label>
    <other_name>Peripheral arterial plethysmography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients with locally advanced or metastatic prostate cancer or high-risk
             prostate cancer.

          -  Scheduled to start ADT for a period of at least one year.

          -  Subject has a history of one or more of the following:

               1. Myocardial infarction

               2. Ischaemic or Haemorrhagic cerebrovascular conditions

               3. Arterial embolic and thrombotic events,

               4. Ischaemic heart disease

               5. Prior coronary artery or iliofemoral artery revascularization (percutaneous or
                  surgical procedures)

               6. Peripheral vascular disease (e.g. significant stenosis (ABPI&lt;0.9), claudication,
                  prior vascular surgery/intervention)

          -  Life expectancy of over 12 months.

          -  WHO performance status of 0-2

          -  Subject is able and has agreed to sign a consent form.

        Exclusion Criteria:

          -  Prior use of ADT. However, prior use of anti-androgens such as Casodex, Chimax,
             Drogenil, and Cyprostat will be allowed.

          -  Prior use of dutasteride/finasteride in past 6 months

          -  Known allergic reaction to Degarelix.

          -  Any psychological, familial, sociological or geographical situation potentially
             hampering compliance with the study protocol and follow-up schedule.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Margel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson Hospital</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Degarelix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

